Heterogeneity of mprF sequences in methicillin-resistant Staphylococcus aureus clinical isolates: Role in cross-resistance between daptomycin and host defense antimicrobial peptides

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7462-7467

  Bayer, Arnold S ^a,b   Mishra, Nagendra N ^a,b   Sakoulas, George ^c,d   Nonejuie, Poochit ^c   Nast, Cynthia C ^b,e   Pogliano, Joseph ^c   Chen, Kuan Tsen ^a   Ellison, Steven N ^a   Yeaman, Michael R ^a,b   Yanga, Soo Jin ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SHARP MEMORIAL HOSPITAL   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; MEMBRANE PHOSPHOLIPID; POLYPEPTIDE ANTIBIOTIC AGENT; AMINOACYLTRANSFERASE; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; BACTERIAL PROTEIN; MPRF PROTEIN, STAPHYLOCOCCUS AUREUS; PHOSPHOLIPID;

ARTICLE; BACTERIAL GENE; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; CELL WALL; CONTROLLED STUDY; CROSS RESISTANCE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE FREQUENCY; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HOST RESISTANCE; IMMUNE DYSREGULATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MPRF GENE; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PHENOTYPIC VARIATION; POINT MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE CHARGE; CELL CLONE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; STAPHYLOCOCCUS INFECTION;

AMINOACYLTRANSFERASES; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; CELL WALL; CLONE CELLS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PHOSPHOLIPIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; STAPHYLOCOCCAL INFECTIONS;

EID: 84912121163     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03422-14     Document Type: Article

References (36)

1. Bayer AS, Schneider T, Sahl H-G. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann. N. Y. Acad. Sci. 1277:139-158. http://dx.doi.org/10.1111/j.1749 -6632.2012.06819.x.
2. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. 2005. Development of daptomycin resistance in vivo in methicillinresistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287. http: //dx.doi.org/10.1128/JCM.43.10.5285-5287.2005.
3. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278. http://dx.doi.org /10.1128/AAC.00719-07.
4. Murthy MH, Olson ME, Wickert RE, Fey PD, Jalali Z. 2008. Daptomycin non-susceptible methicillin-resistant Staphylococcus aureus USA 300 isolate. J. Med. Microbiol. 57:1036-1038. http://dx.doi.org/10.1099/jmm .0.2008/000588-0.
5. Skiest DJ. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656. http://dx.doi .org/10.1128/JCM.44.2.655-656.2006.
6. Mishra NN, Yang S-J, Chen L, Muller C, Saleh-Mghir A, Kuhn S, Peschel A, Yeaman MR, Nast CC, Kreiswirth BN, Crémieux A-C, Bayer AS. 2013. Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms. PLoS One 8:e71151. http://dx.doi.org/10.1371 /journal.pone.0071151.
7. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, Francois P, Peschel A, Bayer AS. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2636-2637. http://dx.doi.org/10.1128/AAC.01415-08.
8. Yang S-J, Nast CC, Mishra NN, Yeaman MR, Fey PD, Bayer AS. 2010. Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob. Agents Chemother. 54:3079-3085. http://dx.doi.org/10.1128/AAC.00122-10.
9. Ernst C, Staubitz P, Mishra NN, Yang SJ, Hornig G, Kalbacher H, Bayer AS, Kraus D, Peschel A. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 5:e1000660. http://dx.doi.org/10 .1371/journal.ppat.1000660.
10. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, Nicholson G, Kalbacher H, Nieuwenhuizen WF, Jung G, Tarkowski A, van Kessel KPM, van Strijp JAG. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J. Exp. Med. 193:1067-1076. http://dx.doi.org/10.1084/jem.193.9.1067.
11. Mishra NN, Bayer AS, Moise PA, Yeaman MR, Sakoulas G. 2012. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomy-cin-naive bacteremic patients. J. Infect. Dis. 206:1160-1167. http://dx.doi .org/10.1093/infdis/jis482.
12. Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, Chen L, Kreiswirth BN, Bayer AS. 2011. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillinresistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4012-4018. http://dx.doi.org/10.1128/AAC.00223-11.
13. Yang S-J, Mishra NN, Rubio A, Bayer AS. 2013. Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance. Antimicrob. Agents Chemother. 57:5658-5664. http://dx.doi.org/10.1128/AAC.01184-13.
14. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA). Antimicrob. Agents Chemother. 53:2312-2318. http://dx .doi.org/10.1128/AAC.01682-08.
15. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, Sawa A, Bayer AS. 2009. Enhanced expression of dltABCD is associated with development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920. http://dx.doi .org/10.1086/648473.
16. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G. 2011. Use of anti-staphylococcal -lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillinresistant Staphylococcus aureus (MRSA): role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163. http://dx.doi.org/10.1093/cid /cir340.
17. Moise PA, Forrest A, Bayer AS, Xiong YQ, Yeaman MR, Sakoulas G. 2010. Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. J. Infect. Dis. 201:233-240. http://dx.doi.org/10.1086/649429.
18. th informational supplement, CLSI document M100-S22. CLSI, Wayne, PA.
19. Boucher HW, Sakoulas G. 2007. Antimicrobial resistance: perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608. http://dx.doi.org/10.1086/520655.
20. Yeaman MR, Sullam PM, Dazin PF, Bayer AS. 1994. Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect. Immun. 62:3416-3423.
21. Yeaman MR, Bayer AS, Koo S-P, Foss W, Sullam PM. 1998. Platelet microbicidal proteins and neutrophil defensin disrupt the Staphylococcus aureus cytoplasmic membrane by distinct mechanisms of action. J. Clin. Invest. 101:178-187. http://dx.doi.org/10.1172/JCI562.
22. Yeaman MR, Puentes SM, Norman DC, Bayer AS. 1992. Partial characterization and staphylocidal activity of thrombin-induced platelet microbicidal protein. Infect. Immun. 60:1202-1209.
23. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3114-3121. http://dx.doi.org/10.1128 /AAC.49.8.3114-3121.2005.
24. Meehl M, Herbert S, Gotz F, Cheung A. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2679-2689. http://dx.doi.org/10 .1128/AAC.00209-07.
25. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, Gotz F. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410. http://dx.doi.org/10.1074/jbc.274.13.8405.
26. Mukhopadhyay K, Whitmire W, Xiong YQ, Molden J, Jones T, Peschel A, Staubitz P, Adler-Moore J, McNamara PJ, Proctor RA, Yeaman MR, Bayer AS. 2007. In vitro susceptibility of Staphylococcus aureus to throm-bin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 153: 1187-1197. http://dx.doi.org/10.1099/mic.0. 2006/003111-0.
27. Yang S-J, Bayer AS, Mishra NN, Meehl M, Ledala N, Yeaman MR, Xiong YQ, Cheung AL. 2012. The Staphylococcus aureus two-component regulatory system, GraRS, senses and confers resistance to selected cationic antimicrobial peptides. Infect. Immun. 80:74-81. http://dx.doi.org /10.1128/IAI.05669-11.
28. Bertsche U, Weidenmaier C, Kuehner D, Yang S-J, Baur S, Wanner S, Francois P, Schrenzel J, Yeaman MR, Bayer AS. 2011. Correlation of daptomycin resistance in a clinical Staphylococcus aureus strain with increased cell wall teichoic acid production and D-alanylation. Antimicrob. Agents Chemother. 55:3922-3928. http://dx.doi.org/10.1128/AAC .01226-10.
29. Oku Y, Kurokawa K, Ichihashi N, Sekimizu K. 2004. Characterization of the Staphylococcus aureus mprF gene, involved in lysinylation of phosphatidylglycerol. Microbiology 150:45-51. http://dx.doi.org/10.1099/mic .0.26706-0.
30. Mehta S, Cuirolo AX, Plata KB, Riosa S, Silverman JA, Rubio A, Rosato RR, Rosato AE. 2012. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivoselected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 56:92-102. http://dx.doi.org/10.1128/AAC .00432-10.
31. Mishra NN, Bayer AS. 2013. Correlation of cell membrane lipid profiles with daptomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 57:1082-1085. http://dx.doi.org/10.1128 /AAC.02182-12.
32. Kilelee E, Pokorny A, Yeaman MR, Bayer AS. 2010. Lysylphosphatidylglycerol attenuates membrane perturbation rather than surface association of the cationic antimicrobial peptide 6W-RP-1 in a model membrane system: implications for daptomycin resistance. Antimicrob. Agents Chemother. 54: 4476-4479. http://dx.doi.org/10 .1128/AAC.00191-10.
33. Ferry T, Bes M, Dauwalder O, Meugnier H, Lina G, Forey F, Vandenesch F, Etienne J. 2006. Toxin gene content of the Lyon methicillinresistant Staphylococcus aureus clone compared with that of other pandemic clones. J. Clin. Microbiol. 44:2642-2644. http://dx.doi.org/10.1128 /JCM.00430-06.
34. Lozano C, Porres-Osante N, Benito D, Zarazaga M, Torres C, Porres-Osante N, Rojo-Bezares B, Sáenz Y, Torres C, Crettaz J, Olarte I. 2013. Changes in genetic lineages, resistance, and virulence in clinical methicil-lin-resistant Staphylococcus aureus in a Spanish hospital. J. Infect. Chemother. 19:233-242. http://dx.doi.org/10.1007/s10156-012-0486-4.
35. Miller CE, Batra R, Cooper BS, Patel AK, Klein J, Otter JA, Kypraios T, French GL, Tosas O, Edgeworth JD. 2012. An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clin. Infect. Dis. 54:591-600. http: //dx.doi.org/10.1093/cid/cir858.
36. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145. http://dx.doi.org/10.1128 /AAC.00039-06.